Yazar "Erbas, Oytun" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Antipsychotic Like Effects of Atorvastatin and Melatonin in a Psychosis Model in Rats
    (2015) Solmaz, Volkan; İnanır, Sema; Delibas, Dursun; Erbas, Oytun
    Amaç: Son yıllarda yapılan çalışmalarda psikoz gibi dopaminerjik bozukluklarla giden hastalıkların patogenezindeserotonerjik bozukluk ve artmış inflamasyon gibi başkamekanizmaların da olabileceğini öne sürülmüştür ve buyolaklarla etkili antipsikotik özelliği olan yeni ilaçlarıngerekliliği belirtilmiştir. Bu çalışmanın amacı, deneyselolarak oluşturulan, apomorfinle tetiklenmiş psikotik dav- ranışlar üzerine atorvastatin ve melatoninin etkileriniincelemektir.Gereç ve Yöntem: Apomorfinle tetiklenmiş steroyotipimodeli in vivo dopamin agonisti yada dopamin anta- gonistlerinin dopaminerjik aktivitelerini değerlendirmekiçin kullanılan deneysel bir modeldir. Çalışmamıza n=6olacak şekilde 7 grup sıçan alındı. Gruplar 10 mg/kg, 20mg/kg atorvastatin, 10 mg/kg ve 20 mg/kg melatonin,%1lik etanol (1 ml/kg), klorpromazin 1mg/kg ve izoto- nik NaCl 1ml/kg olacak şekilde belirlendi. Tüm sıçanlar15er dakikalık periyotlar süresince gözlenerek apomor- finle tetiklenmiş çiğneme hareketleri ve steryotipi skorlarıdeğerlendirildi. Bulgular: 20 mg/kg atorvastatin ve 20 mg/kg mela- tonin çiğneme hareketi skorlarını izotonik verilen grubagöre belirgin derecede azaltmıştı (p<0.05). 10 mg/kgatorvastatin ve 20 mg/kg melatonin verilen gruplarda,izotonik grubuna göre steryotipi skorları istatistiksel olarakanlamlı derecede azalmıştı (p<0.05), ancak bu etki 20mg/kg dozundaki atorvastatin grubunda daha belirgindi(p<0.001).Sonuçlar: Klinik pratikte sıkça kullanılmakta olan antipsi- kotik ajanların fazlaca yan etkileri ve tatmin edici olmayanetkileri göz önüne alındığında antiiflamatuar, nöroptotektifözellikleri olan atorvastatin ve melatoninin yeni tedavialternatiflerine ışık tutabilir.
  • Küçük Resim Yok
    Öğe
    Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary?
    (Springer Heidelberg, 2015) Akdemir, Ali; Sahin, Cagdas; Erbas, Oytun; Yeniel, Ahmet O.; Sendag, Fatih
    Ursodeoxycholic acid is frequently used in cholestatic liver diseases. Also, it protects hepatocytes against oxidative stress induced by hydrophobic bile acids. We investigated the anti-oxidative effect of ursodeoxycholic acid on ischemia/reperfusion injury after ovarian de-torsion in rats. We designed five study groups. Group 1 (n = 6): Sham-operated group; group 2 (n = 6): torsion group; group 3 (n = 6): torsion and ursodeoxycholic acid, group 4 (n = 7): torsion/de-torsion group; and group 5 (n = 7): torsion/de-torsion and ursodeoxycholic acid. After that, ovarian samples were obtained and examined histologically and tissue levels of malondialdehyde were measured. Follicular degeneration, edema and inflammatory cells were significantly decreased in groups 3 and 5 in comparison with groups 2 and 4. Also, groups 4 and 5 were compared in terms of vascular congestion and hemorrhage and these were found to be significantly decreased in group 5. In addition, levels of malondialdehyde were significantly decreased in groups 3 and 5 in comparison with groups 2 and 4. We concluded that ursodeoxycholic acid might be useful to protect the ovary against ischemia and reperfusion injury.
  • Küçük Resim Yok
    Öğe
    Lowering propionic acid levels by regulating gut microbiota with ursodeoxycholic acid appears to regress autism symptoms: an animal study
    (2023) Karakaş, Levent; Solmaz, Volkan; Bagcioglu, Erman; Özkul, Bahattin; Sogut, Ibrahim; Uyanikgil, Yigit; Erbas, Oytun
    Aims: Patients with autism have altered gut microbiata, including higher frequency of bacteroidetes and clostridiales that produce of propionic acid (PPA) –a compound that is established as an autism-inducing agent. We hypothesized that lowering the PPA levels by regulating gut microbiata with ursodeoxycholic acid (UDCA) can regress the autism symptoms. The aim of this study is to examine the potential ameliorating effects of UDCA on a PPA-induced rat model of autism. Methods: Thirty male Wistar albino rats were divided into three groups: controls, PPA-induced (5 days of intraperitoneal 250 mg/kg/day dosage) autism model receiving oral saline, and PPA-induced autism model receiving oral UDCA (100 mg/kg/day). Oral treatments were applied for 15 days. At the end of the 15th day, all rats underwent behavioral tests and MR spectroscopy. At the end of the study, all animals were sacrificed and brain tissue / blood samples were collected for histopathological and biochemical analyses. Results: Sociability test, open field test and passive avoidance learning tests were impaired, similar to the autism behavioral pattern, in PPA recipients; however, results were closer to normal patterns in the PPA+UDCA group. Biochemically, MDA, TNF-alpha, IL-2, IL-17, NF-kB, lactate, NGF and NRF2 levels in brain tissues showed significant differences between controls and the PPA+Saline group, and between the PPA+Saline group and the PPA+UDCA group (p< 0.05, for all). Histopathology showed that PPA injection caused increased glial activity, neural body degeneration, decreased neural count and dysmorphic changes in hippocampal and cerebellar tissues (p<0.01, for all). UDCA treatment significantly ameliorated these changes. Conclusion: UDCA administration has ameliorating effects on PPA-induced autism-like behavioral, biochemical and histopathological changes in rats.